Thus, WIP2W stands out as a potent and selective WT1 inhibitor, and the M—WIP2W nanoformulation appears promising for the therapeutic treatment of refractory CML as well as other WT1-overexpressing malignant cancers. The gene discussed is WT1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.